“I think it’s really important that people keep signing up to these type of trials to push research forward.”
A trial looking at aspirin and esomeprazole to help prevent cancer of the oesophagus (ASPECT)
This trial was done to find out if aspirin and esomeprazole can help prevent cancer of the food pipe (oesophagus) in people with Barrett's oesophagus. It was supported by Cancer Research UK.
More about this trial
Barrett’s oesophagus is a condition where the cells lining the oesophagus change. It is caused by acid from the stomach coming back up into the oesophagus (acid reflux). People with Barrett’s oesophagus have an increased risk of developing oesophageal cancer. Researchers are keen to find a way to reduce this risk.
Esomeprazole is a type of drug called a proton pump inhibitor or PPI. It reduces the amount of acid produced by the stomach. Doctors hoped that it would help stop Barrett’s oesophagus developing into cancer.
Other clinical trials had already shown that aspirin may help prevent oesophageal cancer. But the research team were not sure how useful it is for people with Barrett’s oesophagus. Aspirin can cause stomach ulcers, but doctors hoped that having esomeprazole with aspirin would stop that happening.
Some people in this trial had high dose esomeprazole and some had low dose esomeprazole. Some also took aspirin.
The aim of this trial was to see if esomeprazole with or without aspirin could help stop Barrett’s oesophagus developing into oesophageal cancer.
Summary of results
- 705 people were in group 1 and had low dose esomeprazole and no aspirin
- 704 people were in group 2 and had high dose esomeprazole and no aspirin
- 571 people were in group 3 and had low dose esomeprazole and aspirin
- 577 people were in group 4 and had high dose esomeprazole and aspirin
- 14 people who had low dose esomeprazole and no aspirin
- 12 people who had high dose esomeprazole and no aspirin
- 13 people who had low dose esomeprazole and aspirin
- 9 people who had high dose esomeprazole and aspirin
How to join a clinical trial
Professor Janusz Jankowski
Cancer Research UK
NIHR Clinical Research Network: Cancer
This is Cancer Research UK trial number CRUK/05/006.